FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation - Amgen (NASDAQ:AMGN)
- The Food and Drug Administration approved Amgen Inc.'s Lumakras in combination with Vectibix for KRASG12C-mutated metastatic colorectal cancer, which has received prior chemotherapy.
- The approval is based on the Phase 3 Codebreak 300 study, showing that Lumakras plus Vectibix provides superior progression-free survival compared to standard-of-care.
- The study showed an improved median progression-free survival of 5.6 months for Lumakras plus Vectibix, compared to 2 months on the investigator's choice of care.
- The KRASG12C mutation is present in approximately 3-5% of colorectal cancers, highlighting the targeted nature of this treatment.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left0Leaning Right0Center3Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
